HOME 정보검색 검색결과상세정보

Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited


Bastian Rake | University of Passau

Copenhagen : Danish Research Unit for Industrial Dynamics

39 pages
WorkingPaper ( 13-03 )



Recent empirical contributions emphasize the importance of (potential) market size for the development of new pharmaceuticals. At the same time many scholars point out the importance of of scientific advances for the industry’'s R&D activities. Against this background I analyze the relationship between (potential) market size, technological opportunities, and the number of new pharmaceuticals in the United States. technological opportunities are operationalized as growth rates of the relevant knowledge stock as proposed by Andersen (1999, 1998). I analyze a unique dataset by using an “"entry stock”" Poisson quasi-maximum likelihood estimator. The results reveal a rather robust and significantly positive response of the number of new pharmaceuticals, i.e., new molecular entities or new drug approvals, to market size and technological opportunities


  • Bitzer, J. | Stephan, A. (2007) , A Schumpeter-inspired Approach to the Construction of R&D Capital Stocks , Applied Economics, 39(2):179–189. , VOL.39 No.2 , pp.179 ~ 189
  • Castellacci, F. (2007) , Technological Regimes and Sectoral Differences in Productivity Growth , Industrial and Corporate Change , VOL.16 No.6 , pp.1105 ~ 1145
  • Hamilton, K. S. (2003) , Subfield and Level Classification of Journals : CHI Research Inc.